Probiotic Research for Infant Allergy Prevention
Developed after extensive research, OMNi-BiOTiC® PANDA has demonstrated a profound impact on reducing allergies. Studies revealed an 80% reduction in allergy occurrences in at-risk infants when administered both in the last two months of pregnancy and throughout the infant's first year.
Allergies tend to be prevalent in some families, potentially altering an expecting mother's immune system balance. Specifically, the equilibrium between TH1 and TH2 immune cells can be disrupted, which might be transmitted to the unborn child. However, strategically selected probiotics can restore this balance.
Research supports the use of OMNi-BiOTiC® PANDA by expectant mothers from the 8th week of pregnancy and by infants from day one. Serving as a dietary supplement, it addresses the immunological imbalances between TH1 and TH2 cells.
OMNi-BiOTiC® PANDA is fortified with scientifically-tested bacterial strains that:
The strains' viability and reproducibility are guaranteed up to the product's expiration date.